Summary of COVID-19 lufotrelvir studies
Studies
Meta Analysis
Hide extended summaries
RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.
Feb 2024, NCT05780541, https://clinicaltrials.gov/study/NCT05780541, https://c19p.org/grandits
1. Grandits et al., PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
58 patient lufotrelvir late treatment RCT: 22% higher mortality (p=0.77) and 44% higher hospital discharge (p=0.11).RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.
Feb 2024, NCT05780541, https://clinicaltrials.gov/study/NCT05780541, https://c19p.org/grandits
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.